

**Junin Virus, Candid #1**

**Catalog No. NR-469**

**Product Description:**

Junin virus (JUNV), Candid #1 is a vaccine strain that was developed in the late 1980s from JUNV, XJ, which was isolated from the first human infections with JUNV, the causative agent of Argentine Hemorrhagic Fever (AHF). The heavily attenuated vaccine strain, Candid #1, was developed through collaboration by United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the Argentinian government and the US National Institutes of Health (NIH) by attenuation through serial passage in guinea pigs, mice and FRhK cells. NR-469 lot 70018115 was produced by infecting *Cercopithecus aethiops* kidney cells (Vero E6; ATCC® CCL-1586™) and incubating in Eagle's MEM (ATCC® 30-2003) supplemented with 2% fetal bovine serum (ATCC® 30-2020) for 14 days at 37°C with 5% CO<sub>2</sub>. The first three virus passages at BEI Resources were performed with Plasmocin™ (InvivoGen ant-mpp) in order to remove contaminating mycoplasma, followed by three passages without Plasmocin™ to produce this lot.

**Passage History:**

X(?)/VE6(7) (Prior to deposit at BEI Resources/BEI Resources); X = Unknown; VE6 = Vero E6 cells

**Lot: 70018115**

**Manufacturing Date: 27AUG2019**

TEST	SPECIFICATIONS	RESULTS
<b>Identification by Infectivity in Vero E6 Cells</b>	Cell rounding and detachment	Cell rounding and detachment
<b>Sequencing of Species-Specific Region</b> (~ 820 nucleotides)	≥ 98% identity with JUNV, Candid #1 (GenBank: AY819707.2)	99.8% identity with JUNV, Candid #1 (GenBank: AY819707.2)
<b>Titer by TCID<sub>50</sub> Assay in Vero E6 Cells by qPCR<sup>1</sup></b>	Report results	1.6 × 10 <sup>4</sup> TCID <sub>50</sub> per mL in 14 days at 37°C with 5% CO <sub>2</sub>
<b>Amplification of JUNV Sequence by RT-PCR</b>	~ 990 base pair amplicon	~ 990 base pair amplicon
<b>Sterility (21-day incubation)</b> Harpo's HTYE broth, 37°C and 26°C, aerobic <sup>2</sup> Trypticase Soy broth, 37°C and 26°C, aerobic Sabouraud broth, 37°C and 26°C, aerobic Sheep blood agar, 37°C, aerobic Sheep blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic DMEM with 10% FBS, 37°C and 5% CO <sub>2</sub>	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
<b>Mycoplasma Contamination</b> Agar and broth culture (14-day incubation at 37°C) DNA detection by PCR of extracted Test Article nucleic acid	None detected None detected	None detected None detected

<sup>1</sup>The Tissue Culture Infectious Dose 50% (TCID<sub>50</sub>) endpoint is the 50% infectious endpoint in cell culture. The TCID<sub>50</sub> is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated, just as a Lethal Dose 50% (LD<sub>50</sub>) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID<sub>50</sub> provides a measure of the titer (or infectivity) of a virus preparation.

<sup>2</sup>Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

/Heather Couch/

Heather Couch

13 FEB 2020

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.  
You are authorized to use this product for research use only. It is not intended for human use.

